Has weight loss drug use change way people dine out?
Chef Cindy Hutson and Miami restaurant owners report a decline in large orders as GLP-1 weight loss drugs like Ozempic, Wegovy, Mounjaro, and Zepbound grow in popularity, prompting national chains such as Olive Garden, Chipotle, and McDonald’s to adjust menus for smaller appetites. By late 2025, about 12% of U.S. adults were using these medications, with Miami diners openly discussing their impact on eating habits, though no direct data measures the trend locally.
Miami restaurant owners and chefs say GLP-1 weight loss drugs like Ozempic, Wegovy, Mounjaro, and Zepbound are altering diners’ behavior, with customers ordering smaller portions and lighter meals. Cindy Hutson, chef at Cerveceria La Tropical and former owner of Ortanique, noticed a shift in 2025, where patrons split entrees or opted for salads instead of large fried dishes. She attributed the change to her own experience with Mounjaro, which suppressed her appetite and left her unable to finish meals. The trend extends beyond Miami, with national chains responding to the demand. Olive Garden introduced a ‘lighter portion’ menu in 2026, while Chipotle added a ‘GLP-1 Support Meals’ section featuring high-protein, low-calorie options. McDonald’s CEO Chris Kempczinski acknowledged the trend on an earnings call, noting the company was closely monitoring its impact. Even Smoothie King now markets ‘GLP-1 routine’-supporting drinks. By late 2025, KFF.org estimated that 12% of U.S. adults—about one in eight—were using GLP-1 drugs, with the U.S. accounting for over 60% of global Ozempic and Wegovy sales, according to Statista. While no local data tracks Miami’s dining habits, restaurant owners like Mohamed Alkassar (Cho Funky Asian Bistro) and Mario Palazon (FreshCo Fish) report seeing fewer large orders and more customers openly admitting to using the medications. Palazon observed that stigma around the drugs has faded, with diners now openly discussing their use. His restaurant, known for generous portions, saw uneaten food on plates, prompting conversations with customers. Alkassar also linked the trend to smaller orders and lower-volume dishes, calling GLP-1 drugs ‘more prevalent than ever’ in society. The shift has forced restaurants to adapt, with menus now catering to reduced appetites. While Hutson no longer takes Mounjaro, she said her mindset about eating changed permanently, reflecting a broader cultural shift in dining habits.
This content was automatically generated and/or translated by AI. It may contain inaccuracies. Please refer to the original sources for verification.